Financial Performance - The company's revenue for Q1 2025 was ¥1,147,544,843.46, representing a year-over-year increase of 9.17% compared to ¥1,051,117,744.65 in the same period last year[5]. - Net profit attributable to shareholders decreased by 60.04% to ¥1,997,005.34 from ¥4,996,914.97 in the previous year[5]. - The company reported a basic earnings per share of ¥0.003, down 70.00% from ¥0.01 in the same period last year[5]. - Net profit for the current period was ¥1,721,942.79, a decrease of 66.19% from ¥5,103,538.76 in the previous period[25]. - Total operating revenue for the current period reached ¥1,147,544,843.46, an increase of 9.15% compared to ¥1,051,117,744.65 in the previous period[24]. - Total operating costs amounted to ¥1,145,349,011.63, up from ¥1,060,968,546.72, reflecting a rise of 7.97%[24]. - Total comprehensive income for the current period was ¥14,133,831.65, a significant increase from ¥88,551.05 in the previous period[26]. Cash Flow and Investments - The net cash flow from operating activities improved by 49.46%, reaching -¥93,972,745.38, compared to -¥185,951,326.25 in Q1 2024[5]. - Cash flow from operating activities showed a net outflow of ¥93,972,745.38, an improvement from a net outflow of ¥185,951,326.25 in the previous period[28]. - The company generated ¥1,290,124,316.00 in cash inflows from operating activities, compared to ¥1,155,022,311.60 previously, indicating a growth of 11.65%[27]. - The net cash flow from investing activities decreased by 41.95% to ¥98,738,649.97 compared to ¥170,091,100.29 in Q1 2024[14]. - The net cash flow from investing activities was ¥98,738,649.97, down from ¥170,091,100.29, reflecting a decrease of 42.00%[28]. Assets and Liabilities - The total assets as of March 31, 2025, were ¥7,386,058,803.08, a decrease of 2.57% from ¥7,581,151,714.95 at the end of the previous year[5]. - The company’s total liabilities increased significantly, with current liabilities due within one year rising by 263.73% to ¥578,655,982.47[9]. - Total liabilities decreased to ¥2,903,222,418.51 from ¥3,114,262,583.57, a reduction of about 6.8%[22]. - Total current assets decreased to ¥3,988,725,331.88 from ¥4,205,465,727.75, a decline of approximately 5.2%[20]. - The company’s cash and cash equivalents decreased to ¥670,709,325.85 from ¥799,276,742.37, a decline of approximately 16.1%[20]. - The company reported a total asset decrease to ¥7,386,058,803.08 from ¥7,581,151,714.95, a decline of about 2.6%[22]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 44,531[16]. - The largest shareholder, Zou Jianhan, holds 20.47% of shares, totaling 127,620,000 shares, with 32,000,000 shares pledged[16]. - The number of shares held by the top 10 shareholders represents a significant concentration of ownership, with the top two shareholders holding a combined 38.50%[16]. Other Information - The company experienced a significant increase in receivables financing, which rose by 9809.42% to ¥27,232,674.99 from ¥274,816.00[9]. - The company reported a decrease in financial expenses by 233.69%, resulting in a financial income of -¥20,755,256.40 compared to ¥15,524,364.16 in the previous year[12]. - The company’s investment income decreased by 67.07% to ¥7,180,767.12 from ¥21,805,060.20 in the previous year[12]. - The company has not reported any new product developments or market expansion strategies in the current conference call[18]. - The company reported a significant increase in interest income, which rose to ¥10,537,101.54 from ¥2,675,485.60, marking a growth of 293.36%[25].

Financial Performance - The company's operating revenue for 2024 was ¥4,833,321,898.13, a decrease of 3.92% compared to ¥5,030,460,330.75 in 2023[19] - The net profit attributable to shareholders for 2024 was ¥64,238,678.27, down 37.76% from ¥103,203,187.17 in 2023[19] - The net cash flow from operating activities significantly dropped by 85.45% to ¥130,209,055.41 from ¥895,115,094.07 in the previous year[19] - Basic earnings per share for 2024 were ¥0.10, a decline of 41.18% compared to ¥0.17 in 2023[19] - Total assets at the end of 2024 were ¥7,581,151,714.95, reflecting a decrease of 5.47% from ¥8,019,424,770.29 at the end of 2023[19] - The net assets attributable to shareholders decreased by 3.19% to ¥4,433,152,870.49 from ¥4,579,259,999.09 in 2023[19] - The weighted average return on net assets for 2024 was 1.43%, down from 2.24% in 2023[19] - The net profit after deducting non-recurring gains and losses was ¥24,348,249.49, a decrease of 20.88% from ¥30,774,523.87 in 2023[19] Revenue Breakdown - The main business revenue accounted for ¥4.68 billion, representing 96.79% of total revenue, down 4.73% from ¥4.91 billion in 2023[55] - Health massage products generated ¥3.72 billion, which is 79.59% of main business revenue, showing a slight increase of 0.60% from ¥3.70 billion in 2023[56] - The sales of massage chairs reached ¥2.05 billion, making up 43.75% of main business revenue, a decline of 5.34% from ¥2.16 billion in 2023[55] - The revenue from massage small appliances increased by 8.96% to ¥1.68 billion, representing 35.84% of main business revenue[56] - Domestic sales were approximately ¥1.44 billion, accounting for 30.75% of total revenue, down 5.70% from ¥1.53 billion in 2023[56] - International sales were about ¥3.24 billion, making up 69.25% of total revenue, a decrease of 4.30% from ¥3.39 billion in 2023[56] Market Expansion and Product Development - The company achieved over 50% revenue contribution from its own brand during the reporting period, emphasizing its focus on the health industry and autonomous brand development[28] - The flagship massage chair OG-9598 was launched, featuring a pioneering 5D massage mechanism and AI algorithms, achieving high sales despite its premium price[29] - The company expanded its offline market presence by entering new growth channels such as Sam's Club and Costco, enhancing its competitive position[30] - The brand's net profit increased by 106.89% year-over-year, indicating a significant improvement in profitability during the reporting period[30] - The company is actively exploring new markets along the Belt and Road Initiative, successfully entering multiple countries[28] - The introduction of new products in the mid-range and high-value segments has strengthened the company's competitive edge in the market[29] Research and Development - The company invested 232 million yuan in R&D during the reporting period, focusing on AI algorithms and health detection software[34] - The company has accumulated 2,292 authorized patents, with 1,340 being valid, indicating strong innovation capabilities[34] - The company is focusing on enhancing its "AI + massage" strategy, integrating advanced technologies for personalized health management services[52] - The number of R&D personnel increased by 4.16% to 827, with the proportion of R&D personnel in the total workforce rising to 9.76%[67] Cash Flow and Financial Management - Operating cash inflow decreased by 15.82% to ¥4,760,712,027.04, while operating cash outflow decreased by 2.72% to ¥4,630,502,971.63, resulting in a net cash flow of ¥130,209,055.41, down 85.45% year-on-year[68] - Investment cash inflow surged by 675.57% to ¥1,655,164,383.18, while investment cash outflow increased by 121.83% to ¥1,263,755,921.05, leading to a net cash flow of ¥391,408,462.13[68] - The company's financial expenses saw a significant increase of 631.97% due to a substantial decrease in foreign exchange gains[66] - The company reported an investment income of ¥67,478,588.43, which constituted 73.87% of the total profit, primarily from foreign exchange settlements and structured deposit returns[70] Corporate Governance and Management - The company has a governance structure that complies with relevant laws and regulations, ensuring independence from its controlling shareholders[111] - The company held its annual general meeting with a 42.99% investor participation rate, approving key financial reports and budget plans[114] - The company has a total of 8 directors, with the chairman holding 127,620,000 shares, representing approximately 52.5% of the total shares held by management[116] - The company has maintained its management team since 2010, with the current term ending in September 2026[116] - The company has a diverse management team with backgrounds in various fields, including finance, engineering, and healthcare[118][120] Environmental Compliance - The company has maintained compliance with environmental protection laws and standards, including the "Environmental Protection Law of the People's Republic of China" and various industry standards[150] - The wastewater treatment facility at the subsidiary, Zhangzhou Mengfali, processes wastewater through pre-treatment and a complete flotation system, with a total discharge of 153,000 tons per year[151] - The company has implemented a self-monitoring plan for environmental compliance, with all monitoring data meeting standards during the reporting period[153] - The company has established an emergency response plan for environmental incidents, enhancing its capability to handle such events[154] Social Responsibility - The brand "OGAWA" received six awards during the International Consumer Rights Day event, including "National Leading Brand in Massage Chair Industry" and "National Quality Assurance Product," reflecting strong consumer recognition[161] - The company donated over RMB 200,000 to support flood relief and community development, including a specific donation of RMB 1 million for cardiac rescue projects at Xiamen University First Affiliated Hospital[163]

证券代码：002614 股票简称：奥佳华 公告编号：2025-03 号 债券代码：128097 债券简称：奥佳转债 奥佳华智能健康科技集团股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 股票代码：002614 股票简称：奥佳华 奥佳华智能健康科技集团股份有限公司（以下简称"公司"）根据《深圳证 券交易所股票上市规则》、《深圳证券交易所上市公司自律监管指引第 15 号— —可转换公司债券》等有关规定，现将 2025 年第一季度可转换公司债券（以下 简称"可转债"）转股及公司股份变动情况公告如下： 一、可转债上市发行情况 （一）可转债发行情况 经中国证券监督管理委员会证监许可【2019】1966 号文核准，公司于 2020 年 2 月 25 日公开发行了 1,200 万张可转换公司债券，每张面值 100 元，发行总 额 120,000.00 万元。本次公开发行的可转债向公司在股权登记日收市后登记在册 的原股东优先配售，原股东优先配售后余额部分（含原股东放弃优先配售部分） 通过深圳证券交易所交易系统网上向社会公众投资者发行。认购不足 120 ...

奥佳华智能健康科技集团股份有限公司 2025 年第一季度可转换公司债券转股情况公告 | 证券代码：002614 | 股票简称：奥佳华 | 公告编号：2025-03 | 号 | | --- | --- | --- | --- | | 债券代码：128097 | 债券简称：奥佳转债 | | | 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 股票代码：002614 股票简称：奥佳华 债券代码：128097 债券简称：奥佳转债 转股价格：人民币 9.45 元/股 转股日期：2020 年 9 月 2 日至 2026 年 2 月 25 日 奥佳华智能健康科技集团股份有限公司（以下简称"公司"）根据《深圳证 券交易所股票上市规则》、《深圳证券交易所上市公司自律监管指引第 15 号— —可转换公司债券》等有关规定，现将 2025 年第一季度可转换公司债券（以下 简称"可转债"）转股及公司股份变动情况公告如下： 一、可转债上市发行情况 （一）可转债发行情况 经中国证券监督管理委员会证监许可【2019】1966 号文核准，公司于 2020 年 2 月 25 日公开发 ...

证券代码： 002614 证券简称：奥佳华 奥佳华智能健康科技集团股份有限公司 投资者关系活动记录表 编号：2025-01 投资者关系活动 类别 √ 特定对象调研 □ 分析师会议 □ 媒体采访 □ 业绩说明会 □ 新闻发布会 □ 路演活动 □ 现场参观 □ 其他 参与单位名称及 人员姓名 诺安基金：张伟民； 华创证券：秦一超、樊翼辰。 时间 2025 年 2 月 21 日（周五）上午 10:00 地点 厦门市湖里区安岭二路 31-37 号 8 楼 上市公司接待人 员姓名 李巧巧、陈艺抒、廖晶、林秋燕、杨文为 投资者关系活动 主要内容介绍 一、投资者参观展厅并体验了核心产品 二、公司整体业务和战略规划概况介绍 三、互动交流摘要 1、公司销售费用占比偏高的原因是什么？另外，销售费用 中的折旧费主要是什么费用？ 公司主要经营包括保健按摩（按摩椅、按摩小电器）、健康 环境（新风系统、空气净化器）等健康产品。为提高产业链自主 可控能力，多年来，全球化自主品牌与 ODM 业务双轮驱动发展， 公司持续在全球多个核心市场进行自主品牌布局与建设，目前旗 下"OGAWA 奥佳华"、"ihoco 轻松伴侣"、"BRI 呼博士"、 ...

| 证券代码：002614 | 股票简称：奥佳华 | 公告编号：2025-02 | 号 | | --- | --- | --- | --- | | 债券代码：128097 | 债券简称：奥佳转债 | | | 奥佳华智能健康科技集团股份有限公司 2、债权登记日：2025 年 2 月 24 日； 3、除息日：2025 年 2 月 25 日； 4、付息日：2025 年 2 月 25 日； 5、"奥佳转债"票面利率：第一年 0.40%、第二年 0.60%、第三年 1.00%、 第四年 1.50%、第五年 1.80%、第六年 2.00%； 6、"奥佳转债"本次债券付息的债权登记日为 2025 年 2 月 24 日，凡在 2025 年 2 月 24 日（含）前买入并持有本期债券的投资者享有本次派发的利息；2025 年 2 月 24 日卖出本期债券的投资者不享有本次派发的利息。 7、下一付息期起息日：2025 年 2 月 25 日； 8、下一付息期利率：2.00%。 可转换公司债券 2025 年付息公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、"奥佳 ...

| 证券代码：002614 | 股票简称：奥佳华 | 公告编号：2025-01 号 | | --- | --- | --- | | 债券代码：128097 | 债券简称：奥佳转债 | | 奥佳华智能健康科技集团股份有限公司 2024 年第四季度可转换公司债券转股情况公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 股票代码：002614 股票简称：奥佳华 债券代码：128097 债券简称：奥佳转债 转股价格：人民币 9.45 元/股 转股日期：2020 年 9 月 2 日至 2026 年 2 月 25 日 奥佳华智能健康科技集团股份有限公司（以下简称"公司"）根据《深圳证 券交易所股票上市规则》、《深圳证券交易所上市公司自律监管指引第 15 号— —可转换公司债券》等有关规定，现将 2024 年第四季度可转换公司债券（以下 简称"可转债"）转股及公司股份变动情况公告如下： 一、可转债上市发行情况 （一）可转债发行情况 2022 年 5 月，公司实施 2021 年年度利润分配方案：向全体股东每 10 股派 发现金股利人民币 3 元（含税），不送红 ...

（一）可转债发行情况 | 证券代码：002614 | 股票简称：奥佳华 | 公告编号：2024-58 | 号 | | --- | --- | --- | --- | | 债券代码：128097 | 债券简称：奥佳转债 | | | 奥佳华智能健康科技集团股份有限公司 关于不向下修正奥佳转债转股价格的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、截至 2024 年 12 月 13 日，公司股票已有十五个交易日的收盘价低于当期 转股价格 9.45 元/股的 85%的情形，已触发"奥佳转债"转股价格的向下修正条 件。 2、公司于 2024 年 12 月 13 日召开第六届董事会第七次会议，审议通过了《关 于不向下修正"奥佳转债"转股价格的议案》，公司董事会决定本次不向下修正 "奥佳转债"转股价格，且在未来六个月内（即 2024 年 12 月 14 日至 2025 年 6 月 13 日），如再次触发"奥佳转债"转股价格向下修正条款，亦不提出向下修正 方案。从 2025 年 6 月 16 日重新起算，若再次触发"奥佳转债"转股价格向下修 正条款，届 ...

奥佳华智能健康科技集团股份有限公司（以下简称"公司"）第六届董事会第 七次会议通知以电话、传真及电子邮件等相结合方式于 2024 年 12 月 13 日发出。 会议于 2024 年 12 月 13 日下午 15:30 在厦门市湖里区安岭二路 31-37 号公司八楼会 议室以通讯的方式召开，并获得全体董事确认。本次会议应到董事 9 名，通讯出席 本次会议董事 9 名。公司部分监事、高管列席了本次会议。本次会议为情况紧急召 开的董事会临时会议，召集人已在会议上作出相关说明。本次会议由公司董事长邹 剑寒先生主持，会议符合《中华人民共和国公司法》和公司章程的有关规定。 | 证券代码：002614 | 股票简称：奥佳华 | 公告编号：2024-57 | 号 | | --- | --- | --- | --- | | 债券代码：128097 | 债券简称：奥佳转债 | | | 奥佳华智能健康科技集团股份有限公司 第六届董事会第七次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 截至 2024 年 12 月 13 日，公司股票已有十五个交易日的收盘价低于当期转 ...